Real-World Comprehensive Disease Management of Patients With Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

Real-World Comprehensive Disease Management of Patients With Idiopathic Pulmonary Fibrosis

Published:2019-09-12 Issue:1 Volume:15 Page:4-15
ISSN:1573-398X
Container-title:Current Respiratory Medicine Reviews
language:en
Short-container-title:CRMR

Author:

Mason Wendi¹,McLaughlin Sally²,Dedopoulos Sophy³,Mahoney Erin⁴,Meadows Tonja⁵,Stauffer John L.⁶,Lancaster Lisa H.¹

Affiliation:

1. Department of Medicine, Vanderbilt University, Nashville, Tennessee, TN, United States

2. University of California, San Francisco, California, CA, United States

3. Northwell Health, New Hyde Park, New York, NY, United States

4. Loyola University Medical Center, Maywood, Illinois, IL, United States

5. University of Alabama at Birmingham, Birmingham, Alabama, AL, United States

6. Genentech, Inc., South San Francisco, California, CL, United States

Abstract

Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive, and fatal fibrotic lung disease with a poor prognosis. Antifibrotic therapy slows but does not halt disease progression. Patient education and management needs change during disease progression. Management is complicated by comorbidities, adverse events associated with antifibrotic therapy, and difficulties with long-term oxygen therapy and pulmonary rehabilitation. Treating IPF requires coordination between physicians and nurses in community and interstitial lung disease center settings. This review provides guidance for the healthcare professional who manages the essential aspects of care in IPF from diagnosis, through disease progression, and to the end of life.

Publisher

Bentham Science Publishers Ltd.

Subject

Pulmonary and Respiratory Medicine

Reference103 articles.

1. Raghu G.; Collard H.R.; Egan J.J.; Martinez F.J.; Behr J.; Brown K.K.; Colby T.V.; Cordier J.F.; Flaherty K.R.; Lasky J.A.; Lynch D.A.; Ryu J.H.; Swigris J.J.; Wells A.U.; Ancochea J.; Bouros D.; Carvalho C.; Costabel U.; Ebina M.; Hansell D.M.; Johkoh T.; Kim D.S.; King T.E.; Kondoh Y.; Myers J.; Müller N.L.; Nicholson A.G.; Richeldi L.; Selman M.; Dudden R.F.; Griss B.S.; Protzko S.L.; Schünemann H.J.; An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011,183(6),788-824

2. Raghu G.; Remy-Jardin M.; Myers J.L.; Richeldi L.; Ryerson C.J.; Lederer D.J.; Behr J.; Cottin V.; Danoff S.K.; Morell F.; Flaherty K.R.; Wells A.; Martinez F.J.; Azuma A.; Bice T.J.; Bouros D.; Brown K.K.; Collard H.R.; Duggal A.; Galvin L.; Inoue Y.; Jenkins R.G.; Johkoh T.; Kazerooni E.A.; Kitaichi M.; Knight S.L.; Mansour G.; Nicholson A.G.; Pipavath S.N.J.; Buendía-Roldán I.; Selman M.; Travis W.D.; Walsh S.; Wilson K.C.; Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018,198(5),e44-e68

3. Ley B.; Collard H.R.; King T.E.; Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011,183(4),431-440

4. Fernández Pérez E.R.; Daniels C.E.; Schroeder D.R.; St Sauver J.; Hartman T.E.; Bartholmai B.J.; Yi E.S.; Ryu J.H.; Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010,137(1),129-137

5. Kulkarni T.; Willoughby J.; Acosta Lara Mdel.P.; Kim Y.I.; Ramachandran R.; Alexander C.B.; Luckhardt T.; Thannickal V.J.; de Andrade J.A.; A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival. Respir Med 2016,115,33-38

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey;Pulmonary Therapy;2020-03-19